INDIAN-IMMIGRATION
8.6.2022 10:02:10 CEST | Business Wire | Press release
India has recently become a popular tourist destination for travelers thanks to the breathtaking sceneries it has to offer. Besides adventure travel and cultural tours, wellness tourism in India has emerged as a significant and rapidly expanding tourism segment.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20220608005070/en/
The growth of wellness tourism in India
In 2020, India ranked 12th in the top 20 largest wellness tourism markets in the world, with more than 48.2 million wellness trips. Making use of this travelers' interest, India offers plenty of wellness retreats and resorts for tourists as well as advantageous conditions to get Indian visas.
Many travelers may be confused about the difference between wellness tourism and medical tourism . Medical tourism is about traveling to a different place for specific medical treatments while wellness tourism is associated with the pursuit of maintaining or enhancing travelers’ wellbeing.
Especially, more people are choosing health and wellness tourism in India to recharge their batteries and refresh themselves post pandemic.
Lauren Jane, an American traveler who had a wellness vacation in Ananda in the Himalayas Resort, India, says: “The activities here help me re-balance and relieve stress after the pandemic, while the healthy organic cuisine maintains my health during the trip. I will come back to experience more wellness tourism destinations in India.”
Typical types of wellness tourism in India and corresponding entry documents
India focuses on promoting wellness tourism in 03 key sectors: Meditation, yoga, and massage therapies.
One of the most popular activities on a wellness trip in India is meditation. Travelers will participate in meditation activities in a natural space of plants, water, and clouds. Meditation is a good way for tourists to reset their bodies, and enjoy the moments of relaxation in their souls.
Known as the birthplace of yoga, India promotes the construction of wellness retreats suitable for yoga practices. Most of the retreats are settled close to nature, surrounded by the lush green forests, providing tourists with quiet spaces for doing yoga.
Ayurvedic massage is unique in many wellness retreats in India, bringing relaxing and soothing experiences for tourists. This massage therapy uses oils, herbs, and natural products to help tourists relieve emotional stress, rejuvenate their mind and soul.
“To experience wellness tours in India, travelers just need to prepare a valid passport to apply for an Indian visa, ” said Mrs. Kim, Relationship Manager in Indian Immigration Services.
Useful tips for tourists from Indian Immigration Service Experts
For a pleasant trip to India, travelers should get a visa beforehand. “To choose a reliable partner for making an eVisa, travelers need to consider factors including the fees, processing time, and professionalism of the staff,” Mrs. Kim also said.
Instead of visiting the embassy to apply for a India visa, foreign travelers can obtain an eVisa on the Indian Immigration Services website. As an applicant, travelers need to meet the visa requirements to be granted an Indian eVisa for tourists.
India Immigration Services makes it easier for travelers to apply for an Indian visa online with reasonable Indian eVisa fees. We assisted more than 25,000 customers globally in making eVisas to India. In addition, we also offer Travel Insurance in order to help our customers cover the cost of medical treatments during the trip.
No more complicated process to get a Visa to enter India, travelers now can expect to have a memorable wellness trip in this fascinating country with India Immigration Services.
View source version on businesswire.com: https://www.businesswire.com/news/home/20220608005070/en/
Link:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Corcept Announces CHMP Opinion Recommending EU Marketing Authorization for Lifyorli® (Relacorilant)18.9.2026 14:00:00 CEST | Press release
Corcept Therapeutics Incorporated (NASDAQ: CORT), a commercial-stage company engaged in the discovery and development of medications to treat severe endocrinologic, oncologic, metabolic and neurologic disorders by modulating the effects of the hormone cortisol, today announced that the European Medicines Agency’s Committee for Medicinal Products for Human Use (CHMP) has recommended that the European Commission (EC) should approve relacorilant, combined with the chemotherapy drug nab-paclitaxel, for the treatment of patients with platinum-resistant ovarian cancer. The CHMP’s recommendation is based on positive data from Corcept’s Phase 2 and pivotal Phase 3 ROSELLA trials, in which patients receiving relacorilant combined with nab-paclitaxel experienced improved progression-free and overall survival compared to patients who received nab-paclitaxel alone. The safety profile of relacorilant plus nab-paclitaxel in these trials was consistent with the safety profile of nab-paclitaxel monoth
Enhertu® Recommended for Approval in the EU by CHMP as Adjuvant Treatment for Patients with Residual Disease After Neoadjuvant Treatment for HER2 Positive Early Breast Cancer18.9.2026 14:00:00 CEST | Press release
Recommendation based on DESTINY-Breast05 phase 3 trial results that showed Enhertu reduced the risk of invasive disease recurrence or death by 53% versus T-DM1 Daiichi Sankyo and AstraZeneca’s Enhertu has the potential to become a new standard of care in this early breast cancer setting Enhertu® (trastuzumab deruxtecan) has been recommended for approval in the European Union (EU) as a monotherapy for the adjuvant treatment of adult patients with resected HER2 positive breast cancer who have residual invasive disease after neoadjuvant taxane-based and HER2 targeted treatment. Enhertu is a specifically engineered HER2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) based its positive opinion on results from the DESTINY-Breast05 phase 3 trial presented at th
CHMP Recommends EU Approval of New Indication for Alfasigma’s Jyseleca® (filgotinib), Treatment of Adults With Axial Spondyloarthritis18.9.2026 12:58:00 CEST | Press release
The information contained within this press release is for the purpose of scientific exchange.It is intended for scientific, financial and investor media only.If approved, Jyselecawill be indicated for the treatment of patients with active axial spondyloarthritis (axSpA), both non-radiographic and radiographic forms of the disease, who have responded inadequately to conventional therapy.Despite the availability of multiple treatment options, nearly half of people living with axSpA do not respond adequately to current therapies, and just 10-20% reach inactive disease within 16-24 weeks of initiating treatment.CHMP’s positive opinion is based on findings from the OLINGUITO Phase 3 study, where improvements in the signs and symptoms of axSpA with filgotinib were observed early and maintained over 52 weeks of treatment.Jyselecais already approved in Europe and the United Kingdom, for the treatment of moderate to severe rheumatoid arthritis and ulcerative colitis. Alfasigma S.p.A, a global
IMPACT Therapeutics and Pharmanovia Announce Positive CHMP Opinion for Senaparib, as a Potential First-Line Maintenance Treatment of Advanced High-Grade Epithelial Ovarian, Fallopian Tube, and Primary Peritoneal Cancer18.9.2026 12:38:00 CEST | Press release
For business and medical media only This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260918325771/en/ Stephan Eder, CEO, Pharmanovia IMPACT Therapeutics (07630.HK), a commercial-stage biotechnology company focused on the discovery and development of targeted anti-cancer therapeutics based on synthetic lethality mechanisms, together with global specialty pharmaceutical company Pharmanovia, today jointly announce that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has adopted a positive opinion recommending the granting of a Marketing Authorisation (MA) for the medicinal product Sepalna® (senaparib) intended for the maintenance treatment of advance epithelial ovarian, fallopian tube and primary peritoneal cancer. Following the CHMP’s recommendation for approval, senaparib will be submitted to the European Commission (EC) for final decision. Once approved by the EC, senaparib will
Estithmar Holding Announces Completion of 48.68% Stake Transfer in Shahba Bank to Masaref Holding, a Subsidiary of Estithmar Capital18.9.2026 11:48:00 CEST | Press release
Estithmar Holding Q.P.S.C. announced the completion of the transfer of a 48.68% stake in Shahba Bank to Masaref Holding LLC, subsidiary of Estithmar Capital, Estithmar Holding’s financial services and investments arm. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260918807909/en/ Estithmar Holding Announces Completion of 48.68% Stake Transfer in Shahba Bank to Masaref Holding, a Subsidiary of Estithmar Capital (Photo: AETOSWire) As a shareholder, Masaref Holding intends to support the assessment of proposals aimed at strengthening Shahba Bank’s financial, operational and technological capabilities, including potential capital enhancement, branch network expansion, and the development of products and services for individuals, businesses and SMEs. The proposals may include modernizing banking and operational systems, develop digital services, and strengthen governance, compliance, risk management and cybersecurity to enhance
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom